ABSTRACT
INTRODUCTION
Thalassemia is the most common anemia with hereditary base. 1, 2, 3 Iran is one of the most common countries in terms of major thalassemia. 4, 5 This severe hereditary anemia needs lifelong blood transfusion. According to this modality of treatment, secondary iron overload leads to oxidative stress within the erythrocytes and multiple abnormalities such as metabolic, endocrine and growth abnormalities will occur. 6, 7 Chronic blood transfusion in major thalasssemia or other hemolytic disorders such as Sickle cell anemia could decrease chronic hemolysis and change the micronutrient status. [8] [9] [10] Selenium is a trace element which founded mainly in seafood, meat, and cereals. 11 Selenium is a component of some enzymes such as glutathione peroxidase and iodothyronine deiodinase. 12, 13 Selenium is a component of selenocysteine amino acid which had a role in tissue protection of some free radical such as ferrous choloride and selenium deficiency could lead to tissue damage. 14, 15 14 Different levels of selenium treatments have had different effects on Natural Killer (NK) cell activity in vitro in patients with beta-thalassemia major, as low-dose treatment increased NK activity and vice versa. The study emphasized on the careful use of selenium dosage in these patients. 18 Relationship between the levels of selenium and some infectious diseases 17 beside all the effects that mentioned previously is one of the most important causes that we should know the status of selenium in these patients.
The aim of this study is evaluation of selenium status in a large group of major thalassemia patients and finding a response for the question that "how many patients and whom need micronutrient supplement?"
MATERIALS AND METHODS
This cross-sectional study was carried out on major thalassemia patients in Ali Asghar Hospital in South East of Iran between February and September of 2012. The study was approved in ethic committee of Zahedan medical university. We calculated the sample size with 80% power at the 5% significance level. This could be obtained with 296 cases. We enhanced the sample size in order to ensure that the required sample size would be achieved in case of missing data and to improve the power of the study.
Indeed, we enrolled all major thalassemic patients who were eligible in this period of time. Inclusion criteria were: age above 5 years, documented major thalassemia (with hemoglobin electrophoresis), transfusion dependency, normal kidney and liver function tests. Exclusion criteria were: known liver disease, kidney disease, gastro-intestinal disease, specific diet habit such as vegetarians, and consumption of selenium supplements in any forms. Informed consent was taken from all the participants or their parents in children cases. Blood samples were collected from the selected patients after 12 hours fasting. All blood samples were centrifuged after 45 minute spontaneous coagulation and then stored at -20 degree of centigrade. Selenium was measured by graphite enstrum furnace atomic absorption spectrometry Varian, Australia (Spectr AA 240fs, 2009, USA) in non-metal tubes. The normal range of selenium according to this instrument was 95-140µgr/L. Levels less than 95µgr/L were defined as selenium deficiency and ones higher than 140µgr/L were defined as selenium excess. Data were analyzed by SPSS software and were reported according to mean and Standard Deviation. Statistical analysis was done using T-test, ANOVA and chi-square tests.
RESULTS & DISCUSSION
From all patients (369 cases) with major thalassemia who had more than 5 years-old, 333 cases were eligible and evaluated for selenium status.
Demographic This cross-sectional large study on 333 cases with major thalassemia showed various level of selenium (deficit to excess) in this area in Iran. These results are different with other reports. This variation in selenium status especially, selenium excess is one of the important finding in this large sample size study. In study of Sherief et al, 19 108 cases of major thalassemia with mean age 9.85 ± 4.3 enrolled and evaluated. The majority of cases had selenium deficiency and mean selenium level was 31.5±19.5 μg/L. Different sample size and mean age was differences between out study and their study. In another study in California selenium deficiency was reported in 75% of major thalassemic patients. 20 In study of Claster et al., 21 43 cases with sickle cell anemia and 24 cases with major thalassemia were evaluated. Mean age was 14.5 years-old; iron chelator in majority of cases was deferasirox. Selenium deficiency in this study was 67.5% in SCD and 75% in major thalassemia patients. Some possible reasons for these differences may be different sample size, wider age distribution and different types of iron chelator.
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CONCLUSION
Reports about Selenium status in major thalassemia patients are limited and majority of studies showed low level of selenium in their studied patients. Our study revealed a wide range of selenium level in major thalassemia patients from deficit to excess. Large sample size and wide age distribution are some powers of this study. However, we had some limitations in this study. Since we had a wide range of ages, it was difficult for us to choose a suitable control group for the study and design a case-control study. We did not evaluated diet of the patients, so we do not know possible effect of the diet on the results. It needs further studies to evaluate effect of diet on the selenium level in such study.
Based our results, administration of selenium as an antioxidant to reduce the extent of oxidative damage and related complications in beta thalassemia major still needs further evaluation.
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